| Canagliflozin and cardiovascular and renal events in type 2 diabetes B Neal, V Perkovic, KW Mahaffey, D De Zeeuw, G Fulcher, N Erondu, ... New England Journal of Medicine 377 (7), 644-657, 2017 | 8115 | 2017 |
| Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 5334 | 2019 |
| Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials BPLT Trialists’Collaboration, F Turnbull Lancet 362 (9395), 1527-1535, 2003 | 3133 | 2003 |
| Worldwide access to treatment for end-stage kidney disease: a systematic review T Liyanage, T Ninomiya, V Jha, B Neal, HM Patrice, I Okpechi, M Zhao, ... The Lancet 385 (9981), 1975-1982, 2015 | 2388 | 2015 |
| Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials BPLT Trialists’Collaboration Bmj 336 (7653), 1121-1123, 2008 | 1292* | 2008 |
| Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis M Jun, C Foote, J Lv, B Neal, A Patel, SJ Nicholls, DE Grobbee, A Cass, ... The Lancet 375 (9729), 1875-1884, 2010 | 1207 | 2010 |
| Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis X Xie, E Atkins, J Lv, A Bennett, B Neal, T Ninomiya, M Woodward, ... The Lancet 387 (10017), 435-443, 2016 | 1194 | 2016 |
| Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes T Ninomiya, V Perkovic, BE De Galan, S Zoungas, A Pillai, M Jardine, ... Journal of the American Society of Nephrology 20 (8), 1813-1821, 2009 | 1147 | 2009 |
| Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial J Rosenstock, V Perkovic, OE Johansen, ME Cooper, SE Kahn, N Marx, ... Jama 321 (1), 69-79, 2019 | 1127 | 2019 |
| Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis CA Emdin, K Rahimi, B Neal, T Callender, V Perkovic, A Patel Jama 313 (6), 603-615, 2015 | 1074 | 2015 |
| Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy A Levin, M Tonelli, J Bonventre, J Coresh, JA Donner, AB Fogo, CS Fox, ... The Lancet 390 (10105), 1888-1917, 2017 | 950 | 2017 |
| A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension MH Olsen, SY Angell, S Asma, P Boutouyrie, D Burger, JA Chirinos, ... The Lancet 388 (10060), 2665-2712, 2016 | 941 | 2016 |
| Chronic kidney disease K Kalantar-Zadeh, TH Jafar, D Nitsch, BL Neuen, V Perkovic The lancet 398 (10302), 786-802, 2021 | 899 | 2021 |
| Follow-up of blood-pressure lowering and glucose control in type 2 diabetes S Zoungas, J Chalmers, B Neal, L Billot, Q Li, Y Hirakawa, H Arima, ... New England Journal of Medicine 371 (15), 1392-1406, 2014 | 831 | 2014 |
| SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis BL Neuen, T Young, HJL Heerspink, B Neal, V Perkovic, L Billot, ... The lancet Diabetes & endocrinology 7 (11), 845-854, 2019 | 809 | 2019 |
| Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis R Huxley, CMY Lee, F Barzi, L Timmermeister, S Czernichow, V Perkovic, ... Archives of internal medicine 169 (22), 2053-2063, 2009 | 709 | 2009 |
| Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data Blood Pressure Lowering Treatment Trialists' Collaboration The Lancet 384 (9943), 591-598, 2014 | 660 | 2014 |
| Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials V Perkovic, D de Zeeuw, KW Mahaffey, G Fulcher, N Erondu, W Shaw, ... The lancet Diabetes & endocrinology 6 (9), 691-704, 2018 | 659 | 2018 |
| Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant … K Rahimi, Z Bidel, M Nazarzadeh, E Copland, D Canoy, R Ramakrishnan, ... The Lancet 397 (10285), 1625-1636, 2021 | 589 | 2021 |
| Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study) KW Mahaffey, B Neal, V Perkovic, D de Zeeuw, G Fulcher, N Erondu, ... Circulation 137 (4), 323-334, 2018 | 556 | 2018 |
Bruce NealUNSW Sydney, Imperial College London,The George Institute for Global Health,University of Sydney在 georgeinstitute.org.au 的电子邮件经过验证
